271 related articles for article (PubMed ID: 34923939)
1. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response.
Cienfuegos-Jimenez O; Vazquez-Garza E; Rojas-Martinez A
Curr Gene Ther; 2022; 22(4):303-318. PubMed ID: 34923939
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
3. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
[TBL] [Abstract][Full Text] [Related]
6. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
[TBL] [Abstract][Full Text] [Related]
7. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Schmidt P; Raftery MJ; Pecher G
Front Immunol; 2020; 11():611163. PubMed ID: 33488617
[TBL] [Abstract][Full Text] [Related]
8. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
9. CAR-expressing NK cells for cancer therapy: a new hope.
Xia J; Minamino S; Kuwabara K
Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
[TBL] [Abstract][Full Text] [Related]
10. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
11. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
12. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
[TBL] [Abstract][Full Text] [Related]
14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
17. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
[TBL] [Abstract][Full Text] [Related]
18. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
Hassan SH; Alshahrani MY; Saleh RO; Mohammed BA; Kumar A; Almalki SG; Alkhafaji AT; Ghildiyal P; Al-Tameemi AR; Elawady A
Med Oncol; 2024 Apr; 41(6):127. PubMed ID: 38656354
[TBL] [Abstract][Full Text] [Related]
19. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
20. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]